Bremelanotide Rx

Bremelanotide Rx / Dosing

PT-141 dosage calculator: how reconstitution math works

By the Bremelanotide Rx Editorial Team · 21 min read

Last updated 2026-07-24

TL;DR

There's no official 'PT-141 dosage calculator' from FDA. The approved bremelanotide dose (Vyleesi) is 1.75 mg injected subcutaneously as needed, at least 45 minutes before anticipated activity, no more than once in 24 hours or 8 times a month [1]. Reconstitution calculators used with compounded vials just do arithmetic: (volume of bacteriostatic water) x (vial mg) / (total mL) = mg per dose. The math is simple; the vial's actual concentration and purity are not guaranteed outside FDA-approved product.

What does a PT-141 dosage calculator actually calculate?

A PT-141 dosage calculator (sometimes called a PT 141 reconstitution calculator) is just a unit-conversion tool. It takes three numbers, the amount of peptide in a vial (in milligrams), the amount of liquid you add to reconstitute it (in milliliters), and the dose you want, and tells you how many milliliters to draw into a syringe. The formula is: concentration (mg/mL) = total peptide in vial (mg) divided by total reconstitution volume (mL). Then dose volume (mL) = target dose (mg) divided by concentration (mg/mL). So if a vial holds 10 mg of bremelanotide and you add 2 mL of bacteriostatic water, you get 5 mg/mL. To get a 1.75 mg dose (the FDA-approved amount in Vyleesi), you'd draw 0.35 mL. That's the entire calculation. No app or spreadsheet does anything more sophisticated than that division problem. The catch isn't the math. It's that a calculator can't verify what's actually in the vial. The FDA-approved product, Vyleesi, comes pre-filled in a single-dose auto-injector at a fixed 1.75 mg dose, so there's nothing to calculate at all [1]. Reconstitution calculators exist mainly for compounded or research-grade vials, where the labeled concentration depends entirely on whoever mixed it.

What is the actual FDA-approved PT-141 dose?

The approved dose of bremelanotide (brand name Vyleesi) is 1.75 mg delivered by subcutaneous injection, self-administered as needed at least 45 minutes before anticipated sexual activity [2]. It's approved specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women, not for men and not for postmenopausal women [1]. The two phase 3 trials that supported approval, known as RECONNECT, tested this exact dose in women with HSDD and found modest but statistically significant improvements in desire and reduced distress compared to placebo [3]. FDA approval came in 2019, making bremelanotide one of the peptide drugs approved that year alongside a wave of other new peptide and oligonucleotide therapeutics . Dosing frequency has real limits. Vyleesi's labeling caps use at no more than one dose in 24 hours and no more than 8 doses per month [2]. Those aren't arbitrary; they reflect how the drug was actually dosed in trials and where its safety data exists. Going outside that frequency means you're in territory nobody has studied.

How do you calculate a PT-141 reconstitution dose from a vial?

1 mL10 mg/mL0.175 mL (17.5 units on a U-100 syringe)0.10 mL (10 units)
2 mL5 mg/mL0.35 mL (35 units)0.20 mL (20 units)
3 mL3.33 mg/mL0.53 mL (53 units)0.30 mL (30 units)A standard insulin syringe is marked in units, where 100 units equals 1 mL (a U-100 syringe). That's why reconstitution calculators often output both a mL figure and a unit figure, since most people are drawing with an insulin syringe, not a lab pipette. The math itself takes ten seconds. What it can't tell you is whether the vial genuinely contains 10 mg of actual bremelanotide, whether it's sterile, or whether it's been stored and handled correctly. That's a sourcing and quality problem, not an arithmetic one.

If you're working from a lyophilized (freeze-dried) peptide vial rather than a pre-filled pen, the calculation has three steps, in order. Step one: check the vial's labeled peptide content in milligrams. Step two: decide how much bacteriostatic water (or sterile water) you're adding to reconstitute it. Step three: divide to get concentration, then divide again to get your draw volume for a target dose. Here's a worked table showing common reconstitution scenarios for a 10 mg vial: | Water added | Resulting concentration | Volume for 1.75 mg | Volume for 1.0 mg |

PT-141 (bremelanotide) dosing facts at a glance Key figures from the FDA-approved label and phase 3 trials 1.8 Approved dose (mg, subcutan… 45 Minimum minutes before acti… 1 Max doses per 24 hours 8 Max doses per month Source: PubMed PMID 31893927, 2020; PMID 31599840, 2019

Why can't I just use vascular ED-drug logic for PT-141 dosing?

Because PT-141 doesn't work the way sildenafil or tadalafil work, and that changes what dosing even means. Sildenafil and similar drugs act on blood vessels, increasing blood flow to genital tissue. Bremelanotide acts centrally, on melanocortin receptors in the brain (specifically MC4R), influencing desire and arousal pathways rather than vascular flow directly [4] [5]. Research on the neurobiology of bremelanotide describes this central mechanism as distinct from peripheral vasodilators, which is part of why its side effect profile and dosing logic look so different [5]. This matters for dosing because a vascular drug's effect scales somewhat predictably with local blood flow and half-life. A centrally-acting melanocortin agonist's effect involves receptor activation in the brain and downstream neuroendocrine effects, including transient blood pressure and heart rate changes and, in some study populations, effects on appetite and body weight . One set of phase 1 trials in obese women actually tracked bremelanotide's effect on body weight as a secondary interest, separate from its sexual desire indication . So there's no clean 'if this dose works for erectile blood flow, double it for desire' logic that transfers. The 1.75 mg dose in Vyleesi was arrived at through dose-ranging studies, including a phase 2b trial that found a specific dose-response relationship for desire outcomes before landing on 1.75 mg for phase 3 . That's the number worth anchoring to, not a scaled-up guess.

What if I miss a dose or need a lower/higher amount?

There's no official protocol for adjusting the dose up or down; the approved label is a single 1.75 mg dose, as needed [2]. If a dose is 'missed' in the sense that you didn't take it before an anticipated encounter, you simply don't dose retroactively. It's not a maintenance drug taken on a fixed daily schedule like an SSRI, so there's nothing to 'catch up' on. Some compounding pharmacies and telehealth programs offer bremelanotide at doses below 1.75 mg, often citing an attempt to reduce nausea, which is the most common side effect. There isn't published phase 3 data validating a specific lower dose as effective; the RECONNECT trials tested the 1.75 mg dose that reached approval [3]. A phase 2b dose-ranging study did look at multiple doses and responder rates before that number was chosen , so lower doses were studied at some point in development, just not carried forward as the approved commercial dose. If side effects are the concern, the more direct fix is usually spacing doses further apart, taking it on an empty-ish stomach, or discussing the frequency cap with a prescriber, rather than freelancing a fractional dose based on a reconstitution calculator's guess.

What are the side effects tied to dosing, and how common are they?

Nausea is the single most common side effect of bremelanotide, and it's dose-related enough that trial data break it down clearly. A pooled safety analysis across the clinical development program found nausea affected a large share of women taking 1.75 mg, with rates far exceeding placebo, along with flushing, headache, and injection site reactions as other frequently reported effects [6]. Flushing is the second most reported effect, consistent with the drug's action on melanocortin pathways that also influence skin blood flow and pigmentation in some contexts [6] . Both nausea and flushing tend to be transient, occurring within a few hours of dosing, and tend to lessen with repeated use in many users, though not everyone experiences that fade. Blood pressure needs attention too. Bremelanotide has caused transient increases in blood pressure and decreases in heart rate in trial populations, which is why people with uncontrolled hypertension or cardiovascular disease need specific caution, and why women managing hypertension alongside sexual dysfunction are a distinct clinical consideration reviewed in the literature . This is not a drug to dose casually if blood pressure control is already shaky. For a full breakdown of frequency and severity by symptom, see our pt 141 peptide side effects page, which goes through the safety data in more depth than a dosing calculator ever will.

Does timing before activity actually matter for dosing?

Yes. The approved label specifies dosing at least 45 minutes before anticipated sexual activity [2], and that window isn't arbitrary, it reflects how quickly the drug reaches meaningful central effect after subcutaneous injection. Dosing too close to the anticipated activity risks catching the drug before peak effect; dosing much earlier than needed just means you're carrying side effects (nausea, flushing) for longer without added benefit, since the label's 24-hour and monthly caps assume roughly this timing pattern. There isn't public pharmacokinetic data suggesting a materially different window works better; 45 minutes is what the approved trials used and what the label reflects [2]. If you're using a reconstituted vial from a compounding source rather than the auto-injector, the 45-minute guidance is still the only publicly grounded timing reference available, since there's no separate published timing study for compounded formulations.

Why do PT-141 dosing calculators exist if there's an approved fixed-dose product?

Because a lot of PT-141 in circulation isn't the approved Vyleesi auto-injector. It's sold as a lyophilized peptide, often through research-chemical channels or compounding pharmacies, in vials that need to be reconstituted by the buyer or a pharmacist. That reconstitution step is where the calculator becomes relevant. The approved regulatory pathway for compounded bremelanotide is narrower than people assume. Compounding is governed under 21 U.S.C. 353a, which allows pharmacies to prepare drugs for individual patients under specific conditions [7]. Bulk drug substances used in 503A compounding have to appear on FDA's bulks list under 21 CFR 216.23, or meet other specific criteria [8]. FDA maintains a running list of substances nominated for compounding use, and the regulatory status of a given peptide can change over time as FDA evaluates nominations [9] [10]. This is worth knowing because a calculator, however accurate its math, says nothing about whether the vial you're reconstituting was compounded lawfully, tested for sterility, or verified for actual peptide content. A drug and therapeutics bulletin review of bremelanotide and flibanserin specifically raised concerns about how these drugs got regulatory precedent and how modest their trial effects were relative to the attention they received [11], a useful reality check before treating any dosing math as more authoritative than the underlying product's legitimacy.

How does bremelanotide's dose compare to other HSDD treatments?

Flibanserin (Addyi) is the other FDA-approved option for HSDD, and it works completely differently: it's a daily oral pill affecting serotonin and dopamine pathways, taken every night regardless of anticipated activity, not an as-needed injection [12] [11]. There's no reconstitution or dosing calculator angle for flibanserin because it ships as a fixed daily tablet. Bremelanotide's as-needed, self-injected, 1.75 mg model is structurally different, and a 2021 review specifically compared the regulatory reasoning behind both approvals, questioning whether either drug's effect size justified its approval relative to placebo response rates [11] [13]. A 2024 analysis in the Journal of Sex Research went further, describing the treatment effects in bremelanotide trials as small and raising questions about how clinically meaningful the responder-defined outcomes really were [13]. That's not a reason to dismiss the drug, but it is a reason to keep expectations calibrated. This is a modest-effect medication with a real, FDA-reviewed evidence base behind a specific dose and frequency, not a dramatic on-off switch for desire.

What should I actually do instead of trusting an online calculator alone?

Use a calculator to check your own arithmetic, not to substitute for a legitimate source and a clinician's input. The math behind any PT-141 peptide dosage calculator is genuinely simple, division and multiplication, and you can verify it by hand in under a minute using the concentration formula covered above. What a calculator cannot verify: whether the vial's labeled mg content is accurate, whether it was compounded under a legitimate 503A or 503B facility (503B being the outsourcing facility pathway with its own bulk list under 21 CFR 216.24 [10]), whether it's sterile, and whether the dose makes sense given your blood pressure, cardiovascular history, or other medications. For the FDA-approved route, the product is a fixed-dose auto-injector, so reconstitution math is moot; you inject what's in the pen. If you're pursuing bremelanotide through a provider-reviewed telehealth or clinic pathway, that route typically means a licensed prescriber reviews your history first and the product is filled through a real pharmacy rather than an unverified vial. Bremelanotide Rx tracks these provider-reviewed pathways and the pharmacy partners that fulfill them, which is the more defensible way to handle dosing questions than running numbers through a generic online tool alone. For more on the injection process itself, our pt-141 peptide how to use guide covers technique, and the pt-141 dosage chart lays out dose tables in more visual detail than the walkthrough here.

Is PT-141 the same thing whether I buy it as a peptide vial or get Vyleesi?

Chemically, bremelanotide is bremelanotide, whether it's in an FDA-approved auto-injector or a compounded vial, assuming the vial is accurately labeled and pure. The molecule itself is a synthetic peptide analog of alpha-melanocyte-stimulating hormone, acting on melanocortin receptors, and its pharmacology has been characterized since early development work over a decade before FDA approval [14] [15]. What differs is quality assurance. Vyleesi went through FDA's full approval process, including manufacturing controls verified before approval was granted, documented in FDA's Drugs@FDA database [1] . A peptide vial bought outside that pathway carries none of those guarantees by default, even if the seller's certificate of analysis looks convincing. So when people search for a 'pt 141 peptide reconstitution calculator,' they're usually trying to solve a math problem for a product that sits outside the approval and manufacturing oversight that Vyleesi has. The calculator can get the arithmetic right. It can't get the sourcing question right. Those are separate problems, and conflating them is the most common mistake in this space. If you're weighing where to source from at all, our pt-141 peptide for sale amazon piece and pt 141 peptide for men near me page both cover why marketplace and local-clinic sourcing carries its own set of questions beyond dosing math.

Frequently asked questions

How do I calculate PT-141 dosage from a reconstituted vial?

Divide total peptide mg in the vial by the mL of bacteriostatic water you add to get concentration (mg/mL). Then divide your target dose (commonly 1.75 mg, the FDA-approved amount) by that concentration to get your draw volume in mL. On a U-100 insulin syringe, multiply mL by 100 to get the unit marking to draw to.

What is the standard PT-141 dose?

The FDA-approved dose of bremelanotide (Vyleesi) is 1.75 mg by subcutaneous injection, taken as needed at least 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than 8 times per month [1].

How many units of PT-141 should I draw on an insulin syringe?

It depends entirely on your reconstitution concentration. At 5 mg/mL (a common ratio, like 10 mg peptide in 2 mL water), a 1.75 mg dose equals 35 units on a U-100 syringe. At 10 mg/mL (10 mg in 1 mL water), the same dose equals 17.5 units. Always recalculate for your specific vial and dilution.

Can I use PT-141 daily?

No. The approved label caps bremelanotide at no more than one dose in 24 hours and no more than 8 doses per month [1]. It's designed as an as-needed medication tied to anticipated activity, not a daily maintenance drug like flibanserin, which is taken nightly regardless of activity plans [16].

Is PT-141 dosing the same for men and women?

There's no FDA-approved dose for men. Vyleesi is approved only for hypoactive sexual desire disorder in premenopausal women, based on the RECONNECT phase 3 trials [1] [12]. Any male dosing protocol you see online is not backed by an FDA-reviewed trial in men and should be treated as unverified.

Why does PT-141 cause nausea, and does the dose affect that?

Nausea is the most commonly reported side effect across the bremelanotide clinical development program, tied to its action on central melanocortin receptors rather than a local injection site reaction [5]. It tends to occur within hours of dosing and often lessens with repeated use, though it doesn't disappear for everyone.

What's the difference between PT-141 and sildenafil dosing logic?

Sildenafil works on blood vessels and scales with local vascular effect; bremelanotide works centrally on brain melanocortin receptors (MC4R), influencing desire pathways rather than blood flow directly [7] [19]. That means dosing logic doesn't transfer between the two; you can't reason from one drug's dose-response to the other's.

Can I split a Vyleesi auto-injector dose in half?

The auto-injector delivers a fixed 1.75 mg dose and isn't designed for partial dosing or refilling [4]. There's no published safety or efficacy data for fractional Vyleesi doses. If lower dosing is a goal for side effect reasons, that's a conversation for a prescriber, not something to attempt with the device itself.

How is bremelanotide's dose different from what was tested in early trials?

Bremelanotide's pharmacology was studied for years before approval, including early work in the mid-2000s [3] [15] and dose-ranging phase 2b studies that tested a range of doses before 1.75 mg was selected for the phase 3 RECONNECT trials that led to approval in 2019 [4] [22].

Do reconstitution calculators account for peptide purity or degradation?

No. A calculator only performs the concentration and dose-volume math based on the numbers you enter. It cannot verify that a vial actually contains the labeled amount of intact, pure peptide, or that it hasn't degraded from improper storage. That verification depends on the manufacturing and testing behind the specific product.

Is compounded PT-141 legal to buy and use?

Compounding is regulated under 21 U.S.C. 353a, and bulk substances used in 503A compounding must appear on FDA's approved bulks list under 21 CFR 216.23 or meet specific exceptions [8] [10]. Whether a given bremelanotide vial is lawfully compounded depends on the specific pharmacy and substance status, which FDA periodically updates [9].

How long before it works does PT-141 need to be dosed?

The approved label specifies injecting at least 45 minutes before anticipated sexual activity [1]. This timing reflects how the trials that supported approval were designed and dosed, and there's no published data supporting a meaningfully different window for compounded formulations.

Sources

  1. PubMed, Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder, The Annals of Pharmacotherapy 2020: Approved Vyleesi dose is 1.75 mg subcutaneous, as needed at least 45 minutes before activity, max once per 24 hours and 8 times per month
  2. PubMed, Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment, Journal of Midwifery & Women's Health 2021: Flibanserin is a daily oral treatment for HSDD, contrasted with bremelanotide's as-needed dosing
  3. PubMed, Bremelanotide, 2006: Early pharmacologic characterization of bremelanotide predates its eventual FDA approval by over a decade
  4. PubMed, Bremelanotide: First Approval, Drugs 2019: Vyleesi is FDA-approved as a fixed-dose auto-injector specifically for premenopausal women with HSDD
  5. PubMed, Safety Profile of Bremelanotide Across the Clinical Development Program, Journal of Women's Health 2022: Nausea and flushing are the most commonly reported side effects across the bremelanotide development program
  6. PubMed, Bremelanotide for Treatment of Female Hypoactive Sexual Desire, Neurology International 2022: Bremelanotide acts on central melanocortin receptor pathways rather than peripheral vascular mechanisms
  7. eCFR, 21 CFR 216.23, the 503A Bulks List: Bulk drug substances used in 503A compounding must appear on FDA's approved bulks list or meet specific criteria
  8. FDA, Bulk drug substances nominated for use in compounding (current list): FDA maintains and periodically updates a list of substances nominated for compounding use
  9. Cornell Law School Legal Information Institute, 21 U.S.C. 353a, pharmacy compounding: Pharmacy compounding for individual patients is governed under 21 U.S.C. 353a
  10. eCFR, 21 CFR 216.24, the 503B Bulks List: 503B outsourcing facilities have a separate bulk drug substance list distinct from the 503A pathway
  11. PubMed, Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials, Obstetrics and Gynecology 2019: The RECONNECT phase 3 trials tested the 1.75 mg dose in premenopausal women with HSDD and found statistically significant improvement over placebo
  12. PubMed, Bremelanotide: the female Viagra?, Expert Review of Endocrinology & Metabolism 2006: Bremelanotide's mechanism and development were characterized well before its eventual FDA approval
  13. PubMed, Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent, Drug and Therapeutics Bulletin 2021: A regulatory review questioned the comparative reasoning and effect sizes behind both bremelanotide and flibanserin approvals; flibanserin is a nightly oral pill unlike bremelanotide's as-needed injection
  14. PubMed, The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women, CNS Spectrums 2022: Bremelanotide's central melanocortin mechanism is distinct from peripheral vasodilator drugs used for sexual dysfunction
  15. PubMed, Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder, Journal of Sex Research 2024: An analysis describes bremelanotide's trial treatment effects as small and questions the clinical meaningfulness of responder-defined outcomes
  16. PubMed, Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide, The Journal of Sexual Medicine 2019: A phase 2b dose-ranging study tested multiple bremelanotide doses and responder rates before 1.75 mg was selected for phase 3 trials
  17. PubMed, Management of Hypertension with Female Sexual Dysfunction, Medicina 2022: Blood pressure control is a specific clinical consideration for women considering pharmacotherapy for sexual dysfunction
  18. PubMed, Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials, Diabetes, Obesity & Metabolism 2022: Phase 1 trials in obese women tracked bremelanotide's effect on body weight as a secondary outcome distinct from its sexual desire indication
  19. FDA, Drugs@FDA: FDA-Approved Drug Products database: Vyleesi's approved manufacturing and labeling information is documented in FDA's Drugs@FDA database
  20. PubMed, 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest, Pharmaceuticals 2020: Bremelanotide was among the peptide drugs approved by FDA in the 2019 cohort of peptide and oligonucleotide therapeutics
  21. PubMed, Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin, Biomolecules 2022: Melanocortin receptor activation influences pigmentation and skin-related pathways in addition to central effects